{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=109",
    "query": {
      "intervention": "Branch II",
      "page": 109
    },
    "page_size": 10
  },
  "pagination": {
    "page": 109,
    "page_size": 10,
    "total_count": 4768,
    "total_pages": 477,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=110&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=108&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T12:03:06.693Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01343368",
      "title": "Preservation of Ovarian Function After Hematopoietic Cell Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Non-Hodgkin Lymphoma",
        "Hodgkin Disease",
        "Acute Myeloid Leukemia",
        "Myeloproliferative Disorders"
      ],
      "interventions": [
        {
          "name": "Leuprolide",
          "type": "DRUG"
        },
        {
          "name": "hematopoietic cell transplant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "reduced intensity allogeneic HCT",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "50 Years and older · Female only"
      },
      "enrollment_count": 19,
      "start_date": "2011-07",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-12-05",
      "last_synced_at": "2026-11-11T12:03:06.693Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01343368"
    },
    {
      "nct_id": "NCT02194413",
      "title": "Effects of Healing Touch on Patients Undergoing Hematopoietic Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anxiety Disorder",
        "Fatigue",
        "Hematopoietic/Lymphoid Cancer",
        "Pain"
      ],
      "interventions": [
        {
          "name": "therapeutic touch",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2012-03",
      "completion_date": "2017-01-18",
      "has_results": false,
      "last_update_posted_date": "2017-02-01",
      "last_synced_at": "2026-11-11T12:03:06.693Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02194413"
    },
    {
      "nct_id": "NCT04022161",
      "title": "Effects of Prolonged Delivery of Nitric Oxide Gas on Plasma Reduction-Oxidation Reactions in Cardiac Surgical Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Oxidative Stress",
        "Endothelial Dysfunction"
      ],
      "interventions": [
        {
          "name": "Nitrogen Gas for Inhalation",
          "type": "DRUG"
        },
        {
          "name": "Blood withdrawal",
          "type": "OTHER"
        },
        {
          "name": "Nitric Oxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-07-25",
      "completion_date": "2025-11-24",
      "has_results": false,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-11-11T12:03:06.693Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04022161"
    },
    {
      "nct_id": "NCT02031250",
      "title": "Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "IMRT (Intensity-Modulated Radiation Therapy)",
          "type": "RADIATION"
        },
        {
          "name": "Boost Radiation to Hypoperfused Volumes",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2014-02",
      "completion_date": "2023-02-22",
      "has_results": true,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-11-11T12:03:06.693Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02031250"
    },
    {
      "nct_id": "NCT01987596",
      "title": "Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Childhood Choroid Plexus Tumor",
        "Childhood Medulloblastoma",
        "Childhood Pineoblastoma",
        "Childhood Soft Tissue Sarcoma",
        "Childhood Supratentorial Primitive Neuroectodermal Tumor",
        "Neuroblastoma",
        "Osteosarcoma",
        "Retinoblastoma",
        "Wilms Tumor and Other Childhood Kidney Tumors",
        "Recurrent/Refractory Childhood Hodgkin Lymphoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "1 Year to 25 Years"
      },
      "enrollment_count": 23,
      "start_date": "2013-08",
      "completion_date": "2018-06",
      "has_results": true,
      "last_update_posted_date": "2020-10-29",
      "last_synced_at": "2026-11-11T12:03:06.693Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01987596"
    },
    {
      "nct_id": "NCT03371940",
      "title": "Program ACTIVE II: Behavioral Depression Treatment for Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type2 Diabetes",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Program ACTIVE Exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Program ACTIVE CBT",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Program ACTIVE",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care - No intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2012-01-01",
      "completion_date": "2017-07-31",
      "has_results": true,
      "last_update_posted_date": "2024-05-28",
      "last_synced_at": "2026-11-11T12:03:06.693Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Athens, Ohio • Morgantown, West Virginia",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Athens",
          "state": "Ohio"
        },
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03371940"
    },
    {
      "nct_id": "NCT06559150",
      "title": "A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-cystic Fibrosis Bronchiectasis"
      ],
      "interventions": [
        {
          "name": "Nebulized Ensifentrine Suspension; 3 mg",
          "type": "DRUG"
        },
        {
          "name": "Nebulized Placebo Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 284,
      "start_date": "2024-09-11",
      "completion_date": "2027-09-24",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-11T12:03:06.693Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06559150"
    },
    {
      "nct_id": "NCT00911820",
      "title": "Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Gastric Cancer",
        "Stomach Cancer"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2009-07",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-11-11T12:03:06.693Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Nashville, Tennessee • Dallas, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00911820"
    },
    {
      "nct_id": "NCT01881048",
      "title": "Window of Opportunity Study Targeting the Inflammatory Milieu",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Stage IA Breast Cancer",
        "Stage IB Breast Cancer",
        "Stage II Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Omega-3 fatty acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 42,
      "start_date": "2009-12-08",
      "completion_date": "2015-12-14",
      "has_results": false,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-11-11T12:03:06.693Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01881048"
    },
    {
      "nct_id": "NCT02338843",
      "title": "A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Catecholamine-resistant Hypotension (CRH)",
        "Distributive Shock",
        "High Output Shock",
        "Sepsis"
      ],
      "interventions": [
        {
          "name": "LJPC-501",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "La Jolla Pharmaceutical Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 344,
      "start_date": "2015-03",
      "completion_date": "2017-02-18",
      "has_results": true,
      "last_update_posted_date": "2018-03-27",
      "last_synced_at": "2026-11-11T12:03:06.693Z",
      "location_count": 52,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Loma Linda, California + 39 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02338843"
    }
  ]
}